Evidence map›Paper›PMID 40577481›Full record

ArticleScience advances2025

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

Margaux Saillard, Mara Cenerenti, Patrick Reichenbach, Philippe Guillaume, Ziyang Su, Morteza Hafezi, Julien Schmidt, Julien Cesbron, Raphaël Genolet, Lise Queiroz and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026
    Review
  3. CD4Cancer biology & medicine · 2026
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Margaux SaillardDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-9467-1830
Mara CenerentiLudwig Institute for Cancer Research, Lausanne, Switzerland.ORCID 0000-0001-6630-0557
Patrick ReichenbachDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0000-8673-1936
Philippe GuillaumeDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.
Ziyang SuLudwig Institute for Cancer Research, Lausanne, Switzerland.
Morteza HafeziDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0005-2494-449X
Julien SchmidtDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.
Julien CesbronDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0004-3930-2273
Raphaël GenoletDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-9335-3945
Lise QueirozDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.
Julien RacleDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0100-0323
Jean VillardDivision of Nephrology, Geneva University Hospitals, Geneva, Switzerland.ORCID 0000-0003-2667-7506
Raffaele RenellaPediatric Hematology-Oncology Unit, Division of Pediatrics, Department "Woman-Mother-Child," University Hospital and Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-5041-2308
Olivier MichielinMolecular Modeling Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID 0000-0003-4926-6355
Vincent ZoeteDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2336-6537
Jean-Paul RivalsPlateforme clinique et translationnelle, Centre des thérapies expérimentales, University Hospital and Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-5525-1435
Melita IrvingDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6849-7194
Daniel E SpeiserDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-2031-3250
Alexandre HarariDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-1055-2090
David GfellerDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3952-0930
Olivier AdoteviUniversité Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Francesco CeppiPediatric Hematology-Oncology Unit, Division of Pediatrics, Department "Woman-Mother-Child," University Hospital and Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-9665-3190
George CoukosDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-8813-7367
Pedro RomeroDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9688-2882
Camilla JandusDepartment of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-7405-5747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While cancer immunotherapy has primarily focused on CD8 T cells, CD4 T cells are increasingly recognized for their role in antitumor immunity. The

Indexed as

Antigens, NeoplasmCD4-Positive T-LymphocytesCell- and Tissue-Based TherapyMembrane ProteinsNeoplasmsReceptors, Antigen, T-CellAnimalsCell Line, TumorHumansImmunotherapy, AdoptiveMelanomaMiceReceptors, Antigen, T-Cell, alpha-betaAntigens, NeoplasmCTAG1B protein, humanMembrane ProteinsReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID40577481
PMCPMC12204177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.